Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.

Effect of Dapagliflozin in Comparison With Placebo on Manifestations of Worsening HF In a prespecified expanded, 4-component, composite outcome of time to first HF hospitalization, urgent HF visit, outpatient worsening event, or CV death (total number of events=1211), there was a highly significant benefit of dapagliflozin over placebo: hazard ratio (HR), 0.73 (95% CI, 0.65–0.82), P <0.0001 (Figure 1 ).

also in 132,142 other papers